Abstract: Substances, such as pharmaceuticals and cosmetics, are administered encapsulated within a lipid vesicle, by iontophoresis. An iontophoretic device which conforms to the contours of the body is also provided.

Abstract: This invention provides liposomic composition, containing as active ingredient (-)-N-.alpha.-dimethyl-N-(2-propynylphenylethylamine) (selegilin) and/or salt thereof. This composition contains: 0.1-40% by weight of selegilin and/or a salt thereof, 2 to 40% by weight of lipids, preferably phospholipids, 0 to 10% by weight of cholesterol, 0 to 20% by weight of an alcohol, 0 to 25% by weight of a glycol, 0 to 3% by weight of an antioxidant, 0 to 3% by weight of a preserving agent, 0 to 2% by weight of a viscosity influencing agent, 0 to 50% by weight of cyclodextrin or a cyclodextrin derivative and 30 to 90% by weight of water. This invention relates to pharmaceutical composition, containing the liposomic composition described and if desired, usual filling and diluting agents and other auxiliaries, preferably in oral, parenteral or transdermal form. This invention provides the process for the preparation of liposomic compositions containing selegilin and/or salt thereof.

Abstract: A vaccine for the immunocontraception of mammals is described. The vaccine consists of zona pellucida antigens and an adjuvant encapsulated in a liposome delivery system. The liposome delivery system allows for the slow release of antigen resulting in a prolonged immune response. In particular, after a single injection of the vaccine, levels of anti-zona pellucida antibodies were detected for up to 22 months in seals. Thus, the vaccine according to the present invention is effective after a single dose and is therefore very useful in immunocontraceptive protocols.

Abstract: Liposome-encapsulated opioid analgesic agents delivered by the pulmonary route provide local, or systemic analgesia superior to that produced by the solution form of these agents administered by parentral (intravenous, intramuscular, or subcutaneous injection) or oral routes.

Abstract: Liposome encapsulated local anesthetic or analgesic agents when applied to skin or mucous membranes provided greater local anesthesia and analgesia than the same agents incorporated in conventional vehicles i.e., ointment, cream or lotion.

Abstract: A method for administering a slightly water soluble biologically active compound by topically applying a pharmaceutical composition containing:(a) lipid vesicles with a biologically active compound captured therein;(b) a saturated solution of the biologically active compound; and(c) the biologically active compound in solid form.Optionally this composition is dispersed in a hydrocolloid gel.

Abstract: The present invention provides a novel multiphase drug delivery system which comprises:(a) lipid vesicles with a biologically active compound captured therein;(b) a saturated solution of the biologically active compound; and(c) the biologically active compound in solid form.Optionally this composition is dispersed in a hydrocolloid gel.

Abstract: This invention provides an improved procedure for producing large multilamellar lipid vesicles (MLV), which may be used to encapsulate a biologically active material, particularly lipophilic substances. According to this invention, a lipid film is formed on inert, solid contact masses within a vessel, by evaporating an organic solvent therefrom. Subsequent agitation in the presence of an aqueous liquid, followed by a period in which the vessel remains undisturbed yields the multilamellar vesicles. The procedure permits the encapsulation of both hydrophilic and lipophilic materials.

Abstract: A vaccine for the immunocontraception of mammals is described. The vaccine consists of zona pellucida antigens and an adjuvant encapsulated in a liposome delivery system. The liposome delivery system allows for the slow release of antigen resulting in a prolonged immune response. In particular, after a single injection of the vaccine, levels of anti-zona pellucida antibodies were detected for up to 22 months in seals. Thus, the vaccine according to the present invention is effective after a single dose and is therefore very useful in immunocontraceptive protocols.